Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > ICO 19

<< Previous

Bullboard Posts

Next >>

Post by Keminor74on Apr 16, 2020 10:13am

256 Views

Post# 30915939

ICO 19

It is open for debate,but I was reading the press release and realized how can you affored to appoint Dr.Kishor Wasan as Director of Research for the Company if there is no plan going forward with this product, I'm not sure what is the plan but reading little further you can see that Dr. Kishor Wasan will initially focus his efforts on the further development of iCo 019 via partnerships and collaborations.

My opinion is they have already something on ago and they needed the expertise of Dr.Kishor Wasan to put the plan in place as Dr. Wasan led the research team at the Wasan lab at the University of British Columbia that developed what has become iCo 019.

Any other opinion?

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security